1. A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Issue 7 (7th June 2021) Authors: Khan, Sahar; LeBlanc, Richard; Gyger, Martin; White, Darrell; Kaufman, Johnathan; Jazubowiak, Andrzej; Gul, Engin; Paul, Harminder; Le, Lisa W.; Lau, Anthea; Li, Zhihua; Trudel, Suzanne Journal: Leukemia & lymphoma Issue: Volume 62:Issue 7(2021) Page Start: 1721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. Issue 4 (31st August 2022) Authors: McCurdy, Arleigh; Louzada, Martha; Venner, Christopher P.; Visram, Alissa; Masih‐Khan, Esther; Kardjadj, Moustafa; Jimenez‐Zepeda, Victor H.; LeBlanc, Richard; Sebag, Michael; Song, Kevin; White, Darrell; Mian, Hira; Stakiw, Julie; Reiman, Anthony; Aslam, Muhammad; Kotb, Rami; Gul, Engin; Reece, ... Journal: EJHaem Issue: Volume 3:Issue 4(2022) Page Start: 1252 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. (13th October 2020) Authors: Belch, Andrew; Bahlis, Nizar; White, Darrell; Cheung, Matthew; Chen, Christine; Shustik, Chaim; Song, Kevin; Tosikyan, Axel; Dispenzieri, Angela; Anderson, Kenneth; Brown, Diane; Robinson, Suzanne; Srinivasan, Shankar; Facon, Thierry Journal: Cancer medicine Issue: Volume 9:Number 23(2020) Page Start: 8923 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Issue 10027 (9th April 2016) Authors: Lonial, Sagar; Weiss, Brendan M; Usmani, Saad Z; Singhal, Seema; Chari, Ajai; Bahlis, Nizar J; Belch, Andrew; Krishnan, Amrita; Vescio, Robert A; Mateos, Maria Victoria; Mazumder, Amitabha; Orlowski, Robert Z; Sutherland, Heather J; Bladé, Joan; Scott, Emma C; Oriol, Albert; Berdeja, Jesus; Ghari... Journal: Lancet Issue: Volume 387:Issue 10027(2016) Page Start: 1551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and Safety of Busulfan‐Based Conditioning Regimens for Multiple Myeloma. (29th April 2013) Authors: Reece, Donna; Song, Kevin; LeBlanc, Richard; Mezzi, Khalid; Olujohungbe, Ade; White, Darrell; Zaman, Faraz; Belch, Andrew Journal: Oncologist Issue: Volume 18:Number 5(2013) Page Start: 611 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Issue 12 (December 2015) Authors: Richardson, Paul G; Jagannath, Sundar; Moreau, Philippe; Jakubowiak, Andrzej J; Raab, Marc S; Facon, Thierry; Vij, Ravi; White, Darrell; Reece, Donna E; Benboubker, Lotfi; Zonder, Jeffrey; Tsao, L Claire; Anderson, Kenneth C; Bleickardt, Eric; Singhal, Anil K; Lonial, Sagar Journal: Lancet Issue: Volume 2:Issue 12(2015) Page Start: e516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. (5th July 2017) Authors: Dimopoulos, Meletios A.; Lonial, Sagar; White, Darrell; Moreau, Philippe; Palumbo, Antonio; San‐Miguel, Jesus; Shpilberg, Ofer; Anderson, Kenneth; Grosicki, Sebastian; Spicka, Ivan; Walter‐Croneck, Adam; Magen, Hila; Mateos, Maria‐Victoria; Belch, Andrew; Reece, Donna; Beksac, Meral; Bleickardt, ... Journal: British journal of haematology Issue: Volume 178:Number 6(2017) Page Start: 896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T‐cell lymphoma. Issue 5 (29th October 2014) Authors: Toumishey, Ethan; Prasad, Angeli; Dueck, Greg; Chua, Neil; Finch, Daygen; Johnston, James; van der Jagt, Richard; Stewart, Doug; White, Darrell; Belch, Andrew; Reiman, Tony Journal: Cancer Issue: Volume 121:Issue 5(2015) Page Start: 716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Low‐depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution. Issue 2 (29th May 2019) Authors: Elnenaei, Manal O.; Knopf, Philipp; Cutler, Samuel D.; Sinclair, Keaton; Abou El Hassan, Mohamed; Greer, Wenda; Goudie, Marissa; Wagner, Julie; White, Darrell; Couban, Stephen; Forward, Nicholas; Gaston, Daniel; Campbell, Clinton J.V. Journal: Clinical genetics Issue: Volume 96:Issue 2(2019) Page Start: 163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗